Locations:
Search IconSearch
March 7, 2018/Cancer/Innovations

New Imaging Technology May Help Predict Aggressiveness of Lung Cancer

Research supported by a recent $3.16 million NCI grant

velcheti-grant_650x450

A computer-extracted feature analysis of digitalized tissue imaging could soon help identify patients with early stage non-small cell lung cancer (NSCLC) who are likely to face early recurrence after surgery.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

With this information, oncologists could more accurately determine which lung cancer patients should undergo aggressive post-surgery chemotherapy and identify patients who could benefit from alternate strategies like immunotherapy to improve chance of cure after surgery.

“Current standard practice includes surgery for most early-stage lung cancer patients,” says Vamsidhar Velcheti, MD, Associate Director for Immuno-Oncology Research, Cleveland Clinic Cancer Center. “Post-surgery chemotherapy can provide added benefit for some patients, but right now we don’t have tests to identify who could benefit.”

The National Cancer Institute recently awarded Dr. Velcheti and Anant Madabhushi, PhD, a $3.16 million grant to advance this promising research project.

“What we’ve proposed with this grant is to create the first actual predictive analysis for early-stage lung cancer to figure out who is going to benefit from chemotherapy,” says Dr. Madabhushi, founding Director of the Center for Computational Imaging and Personalized Diagnostics at Case Western Reserve University School of Engineering. “We haven’t yet definitively shown that it’s predictive, because we haven’t done clinical trials. That is what this new grant will help us to do.”

Dr. Velcheti, Dr. Madabhushi and six collaborators published research regarding the technique in late 2017 in Nature’s Scientific Reports. This retrospective study showed that using a computational histomorphometric image classifier of digitized tissue Hematoxylin and Eosin (H&E) microarray slides could predict recurrence.

Advertisement

Caption: Representative TMA tissue spots of recurrent (top row) and non-recurrent (bottom row) NSCLC with corresponding feature maps: Recurrence TMA with (a,e) nuclear shape feature, (b,f) texture feature map (Haralick standard deviation intensity correlation), (c,g) nuclear cluster graph feature map, and (d,h) nuclear orientation. Image republished from: Wang X, Janowcyzk A, Zhou Y, Thawani R, Fu P, Schalper K, Velcheti V, Madabhushi A. Prediction of recurrence in early stage non-small cell lung cancer using computer extracted nuclear features from digital H&E images. Scientific Reports. 2017;7:13543. doi:10.1038/s41598-017-13773-7

The classifier uses computer-assisted digital analysis to identify known clinicopathologic clues, such as tumor size and nuclear morphometric features, of recurrence in early NSCLC to quantify risk. The next step is to show explicitly that the approach can also identify patients who will receive added benefit from adjuvant chemotherapy.

“If this test can identify patients who have a high risk of cancer recurrence, that means other patients may potentially be spared the side effects of chemotherapy,” Dr. Velcheti says.

Advertisement

Related Articles

Doctors working on MGUS screening study
March 18, 2024/Cancer/Research
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Hematologist at Cleveland Clinic
March 14, 2024/Cancer/Blood Cancers
Advances in Mantle Cell Lymphoma Treatment (Podcast)

Global R&D efforts expanding first-line and relapse therapy options for patients

Physician with patient
March 6, 2024/Cancer/Research
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Dr. Jagadeesh at Cleveland Clinic
February 28, 2024/Cancer/Blood Cancers
Treating Patient with Systemic T-Cell Lymphoma and Graft-Versus-Host Disease

A case study on the value of access to novel therapies through clinical trials

Doctor measuring patient's waist size
February 26, 2024/Cancer/Research
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024/Cancer/Research
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456

How antibody drug conjugates work
February 13, 2024/Cancer/Research
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

CQD-4445459-rotz-650×450
February 7, 2024/Cancer
Advances in Bone Marrow Transplant Have Improved Outcomes in Fanconi Anemia

Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients

Ad